drugset / Trial / NCT01823939

PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera

NCT01823939

Phase 1 Completed 26 enrolled PATH
RandomizedSingle-groupOpen-labelTreatment

Summary

This study will assess if the pharmacokinetics, safety and tolerability of iOWH032 are grossly different in 1) Bangladeshi healthy population and 2) Bangladeshi cholera patients. This is not a hypothesis-driven research study.

Timeline

Start
2013-05
Primary completion
2013-11
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject iOWH032 Small molecule 300 mg Oral